Management of pemphigus during COVID-19 pandemic era: An experience of single centre

被引：0

作者：

Noor, Sahibzada Mahmood ^{[1
]}

Sagheer, Farah ^{[1
]}

Sardar, Adan ^{[1
]}

机构：

[1] Lady Reading Hosp, Dept Dermatol, Peshawar, Pakistan

来源：

JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION | 2025年 / 75卷 / 03期

关键词：

COVID-19; Pemphigus; Severe acute respiratory syndrome coronavirus therapy; Rituximab;

D O I：

10.47391/JPMA.10935

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The management of pemphigus vulgaris disease was challenging during the coronavirus diseases-2019 pandemic. The current study was planned to determine whether or not rituximab increases the risk and severity of coronavirus diseases-2019 infection in pemphigus vulgaris patients. The retrospective study was conducted at the Lady Reading Hospital, Peshawar, Pakistan, and comprised data from the dermatology unit of 34 diagnosed cases of pemphigus vulgaris who received rituximab treatment from March 2020 to March 2022. The mean age of the patients was 36.58 +/- 12.44 years. Majority of patients 28(82.3%) received rituximab as a second-line therapy, while 6(17.64%) were given it as a first-line therapy. Only 1(2.9%) patient developed mild covid pneumonia, and did not need in-patient care or faced oxygen dependence. There was a significant weak association between coronavirus diseases-2019 positivity with age (p=0.000). Rituximab therapy could be given to pemphigus patients during the pandemic, but only when necessary.

引用

页码：469 / 471

页数：3

共 12 条

[1]

Abdollahimajd F, 2020, ARCH ACAD EMERG MED, V8

[2] Rituximab as the treatment of pemphigus vulgaris in theCOVID-19 pandemic era: A narrative review [J].

Beyzaee, Amir Mohammad ;

Rahmatpour Rokni, Ghasem ;

Patil, Anant ;

Goldust, Mohamad .

DERMATOLOGIC THERAPY, 2021, 34 (01)

[3] Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect [J].

Chen, D. M. ;

Odueyungbo, A. ;

Csinady, E. ;

Gearhart, L. ;

Lehane, P. ;

Cheu, M. ;

Maho-Vaillant, M. ;

Prost-Squarcioni, C. ;

Hebert, V ;

Houivet, E. ;

Calbo, S. ;

Caillot, F. ;

Golinski, M. L. ;

Labeille, B. ;

Picard-Dahan, C. ;

Paul, C. ;

Richard, M. A. ;

Bouaziz, J. D. ;

Duvert-Lehembre, S. ;

Bernard, P. ;

Caux, F. ;

Alexandre, M. ;

Ingen-Housz-Oro, S. ;

Vabres, P. ;

Delaporte, E. ;

Quereux, G. ;

Dupuy, A. ;

Debarbieux, S. ;

Avenel-Audran, M. ;

D'Incan, M. ;

Bedane, C. ;

Beneton, N. ;

Jullien, D. ;

Dupin, N. ;

Misery, L. ;

Machet, L. ;

Beylot-Barry, M. ;

Dereure, O. ;

Sassolas, B. ;

Benichou, J. ;

Musette, P. ;

Joly, P. .

BRITISH JOURNAL OF DERMATOLOGY, 2020, 182 (05) :1111-1119

[4] The effects of COVID-19 infection on the mortality of patients receiving rituximab therapy [J].

Ekin, Ali ;

Coskun, Belkis Nihan ;

Dalkilic, Ediz ;

Pehlivan, Yavuz .

IRISH JOURNAL OF MEDICAL SCIENCE, 2023, 192 (04) :1959-1973

[5] Pemphigus andCOVID-19: Critical overview of management with a focus on treatment choice [J].

Elmas, Omer Faruk ;

Demirbas, Abdullah ;

Tursen, Umit ;

Atasoy, Mustafa ;

Lotti, Torello .

DERMATOLOGIC THERAPY, 2020, 33 (06)

[6] Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV) [J].

Joly, P. ;

Horwath, B. ;

Patsatsi, A. ;

Uzun, S. ;

Bech, R. ;

Beissert, S. ;

Bergman, R. ;

Bernard, P. ;

Borradori, L. ;

Caproni, M. ;

Caux, F. ;

Cianchini, G. ;

Daneshpazhooh, M. ;

De, D. ;

Dmochowski, M. ;

Drenovska, K. ;

Ehrchen, J. ;

Feliciani, C. ;

Goebeler, M. ;

Groves, R. ;

Guenther, C. ;

Hofmann, S. ;

Ioannides, D. ;

Kowalewski, C. ;

Ludwig, R. ;

Lim, Y. L. ;

Marinovic, B. ;

Marzano, A., V ;

Mascaro, J. M. Jr Jr ;

Mimouni, D. ;

Murrell, D. F. ;

Pincelli, C. ;

Squarcioni, C. P. ;

Sardy, M. ;

Setterfield, J. ;

Sprecher, E. ;

Vassileva, S. ;

Wozniak, K. ;

Yayli, S. ;

Zambruno, G. ;

Zillikens, D. ;

Hertl, M. ;

Schmidt, E. .

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2020, 34 (09) :1900-1913

[7] Pemphigus-The Crux of Clinics, Research, and Treatment during the COVID-19 Pandemic [J].

Marinovic, Branka ;

Mise, Josko ;

Jukic, Ines Lakos ;

Bukvic Mokos, Zrinka .

BIOMEDICINES, 2021, 9 (11)

[8] Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab [J].

Rouge, Lionel ;

Chiang, Nancy ;

Steffek, Micah ;

Kugel, Christine ;

Croll, Tristan I. ;

Tam, Christine ;

Estevez, Alberto ;

Arthur, Christopher P. ;

Koth, Christopher M. ;

Ciferri, Claudio ;

Kraft, Edward ;

Payandeh, Jian ;

Nakamura, Gerald ;

Koerber, James T. ;

Rohou, Alexis .

SCIENCE, 2020, 367 (6483) :1224-+

[9]

Sodeifian F, 2022, ACTAS DERMO-SIFILOGR, V113, P157, DOI [10.1016/j.ad.2022.01.023, 10.1016/j.ad.2021.08.005]

[10] Can rituximab be used in the treatment of pemphigus vulgaris during the COVID-19 pandemic? [J].

Uzuncakmak, Tugba Kevser ;

Ozkoca, Defne ;

Askin, Ozge ;

Kutlubay, Zekayi .

DERMATOLOGIC THERAPY, 2021, 34 (01)

← 1 2 →